![](https://htpdigital.com/wp-admin/admin-ajax.php?action=kernel&p=image&src=%7B%22file%22%3A%22wp-content%2Fuploads%2F2022%2F12%2FComp-Thera-2.jpg%22%2C%22thumbnail%22%3A%221200%2C800%2C%22%7D&hash=af23447b)
![](https://htpdigital.com/wp-admin/admin-ajax.php?action=kernel&p=image&src=%7B%22file%22%3A%22wp-content%2Fuploads%2F2022%2F12%2FComp-Thera-6.jpg%22%2C%22thumbnail%22%3A%221200%2C800%2C%22%7D&hash=b1e05e7d)
![](https://htpdigital.com/wp-admin/admin-ajax.php?action=kernel&p=image&src=%7B%22file%22%3A%22wp-content%2Fuploads%2F2022%2F12%2FComp-Thera-4.jpg%22%2C%22thumbnail%22%3A%221200%2C800%2C%22%7D&hash=06e00e36)
Turning powerful new Complement System insights ninto innovative treatments
Complement Therapeutics is a biotechnology company undertaking innovative research into diseases related to the body’s Complement System, in particular Geographic Atrophy.
Geographic Atrophy is a chronic and progressive eye condition that eventually culminates in blindness. Currently there is no available treatment.
The company is a spinout from The University of Manchester. It was founded by Professor Paul Bishop, Professor Simon J. Clark and Dr Richard Unwin, who have international reputations and world-leading Complement System expertise.
HTP were briefed by the founders to develop a website that would help attract funding to pursue further research and at the same time educate and inform visitors about Complement System diseases – especially Geographic Atrophy – and the potential of the company’s work to benefit the lives of millions.
Turning powerful new Complement System insights into innovative treatments
Complement Therapeutics is a biotechnology company undertaking innovative research into diseases related to the body’s Complement System, in particular Geographic Atrophy.
Geographic Atrophy is a chronic and progressive eye condition that eventually culminates in blindness. Currently there is no available treatment.
The company is a spinout from The University of Manchester. It was founded by Professor Paul Bishop, Professor Simon J. Clark and Dr Richard Unwin, who have international reputations and world-leading Complement System expertise.
HTP were briefed by the founders to develop a website that would help attract funding to pursue further research and at the same time educate and inform visitors about Complement System diseases – especially Geographic Atrophy – and the potential of the company’s work to benefit the lives of millions.
In 2022 Complement Therapeutics was awarded seed finance of 5 million euros to fund further pre-clinical and early clinical development. The company continues to pursue its ground-breaking work, now through a considerably expanded team.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
This website uses the following additional Youtube cookies:
Please enable Strictly Necessary Cookies first so that we can save your preferences!